Bao Bui, MD
Cardiovascular Disease · Fountain Valley, CANPI 1801099593
Payments from drug & device makers
Across 849 payments — averaging $506.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$113K
- Merck$107K
- Johnson & Johnson$66K
- Boehringer Ingelheim$55K
- Lilly USA, LLC$50K
- AstraZeneca$29K
- plus $9K from 30 others
What the payments were for
- Consulting fees$1,6410%
- Speaking & faculty fees$366,05485%
- Travel & lodging$42,03410%
- Food & beverage$20,5155%
- Education$1870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 78 | $112,953 |
| Merck | 121 | $107,173 |
| Johnson & Johnson | 145 | $66,152 |
| Boehringer Ingelheim | 75 | $55,357 |
| Lilly USA, LLC | 53 | $50,021 |
| AstraZeneca | 125 | $29,365 |
| Bayer | 24 | $1,919 |
| Novartis | 66 | $1,422 |
| Sun Pharmaceutical Industries Inc. | 8 | $697 |
| E.r. Squibb & Sons, L.L.C. | 37 | $667 |
| Biotronik Inc. | 7 | $563 |
| UCB, Inc. | 4 | $460 |
| Janssen Scientific Affairs, LLC | 7 | $416 |
| Shockwave Medical, Inc | 3 | $396 |
| Amgen | 13 | $379 |
| Pfizer | 23 | $294 |
| Incyte Corporation | 2 | $243 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $232 |
| Lexicon Pharmaceuticals, Inc. | 5 | $187 |
| Almirall LLC | 2 | $172 |
| Venclose Inc. | 4 | $150 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $141 |
| Bristol Myers Squibb | 1 | $139 |
| Abiomed | 1 | $116 |
| Abbott | 1 | $112 |
| Sanofi | 1 | $94 |
| Amarin Pharma, Inc. | 4 | $87 |
| Cardiovascular Systems Inc. | 2 | $82 |
| LEO Pharma Inc. | 2 | $82 |
| Scpharmaceuticals Inc. | 4 | $79 |
| Sanofi-aventis U.S. LLC | 4 | $76 |
| Philips North America LLC | 1 | $55 |
| Dermira, Inc. | 1 | $50 |
| Boston Scientific | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 1 | $38 |
| Kestra Medical Technology Services, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$161,269
- JARDIANCE$100,240
- Ozempic$88,117
- XARELTO$64,560
- FARXIGA$27,459
- Kerendia$1,449
- ILUMYA$372
- Cimzia$260
- Vascular Lithotripsy$228
- COSENTYX$212
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$168
- Otezla$139
- ABSORICA$126
- ABSORICA LD$122
- Sotyktu$117
- TALTZ$116
- Impella$116
- Inpefa$116
- Repatha$113
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$112
How this compares
$430,431 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 298 | $314,028 |
| JardianceEmpagliflozin | 285 | $308,482 |
| EntrestoSacubitril/Valsartan | 192 | $219,545 |
| OzempicSemaglutide | 149 | $184,116 |
| FarxigaDapagliflozin Propanediol | 184 | $178,040 |
| KerendiaFinerenone | 113 | $129,471 |
| BrilintaTicagrelor | 126 | $113,758 |
| VerquvoVericiguat | 58 | $55,912 |
| EliquisApixaban | 43 | $48,298 |
| Repatha SureclickEvolocumab | 79 | $45,290 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $44,758 |
| RybelsusSemaglutide | 23 | $44,565 |
| VascepaIcosapent Ethyl | 77 | $35,887 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $34,377 |
| CreonLipase/Protease/Amylase | 21 | $29,008 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere | $29,365 | $326,174355 claims |
| Boehringer IngelheimJardiance, Tradjenta | $55,357 | $317,751301 claims |
| Johnson & JohnsonXarelto | $66,152 | $314,028298 claims |
| Novo NordiskOzempic, Rybelsus | $112,953 | $228,681172 claims |
| NovartisEntresto | $1,422 | $219,545192 claims |
| BayerKerendia | $1,919 | $129,471113 claims |
| MerckVerquvo, Januvia, Janumet | $107,173 | $82,36484 claims |
| PfizerEliquis | $294 | $48,29843 claims |
| Lilly USA, LLCTrulicity | $50,021 | $23,12720 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $187 | $14,14325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Fountain Valley
- Vinod MalhotraFountain Valley$1.5M
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.